JP2017526361A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526361A5
JP2017526361A5 JP2017511182A JP2017511182A JP2017526361A5 JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5 JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5
Authority
JP
Japan
Prior art keywords
signaling
domain
binding domain
car
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526361A (ja
JP6614619B2 (ja
Filing date
Publication date
Priority claimed from GBGB1415347.2A external-priority patent/GB201415347D0/en
Application filed filed Critical
Publication of JP2017526361A publication Critical patent/JP2017526361A/ja
Publication of JP2017526361A5 publication Critical patent/JP2017526361A5/ja
Application granted granted Critical
Publication of JP6614619B2 publication Critical patent/JP6614619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511182A 2014-08-29 2015-08-28 シグナル伝達系 Active JP6614619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1415347.2A GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system
GB1415347.2 2014-08-29
PCT/GB2015/052494 WO2016030691A1 (en) 2014-08-29 2015-08-28 Signalling system

Publications (3)

Publication Number Publication Date
JP2017526361A JP2017526361A (ja) 2017-09-14
JP2017526361A5 true JP2017526361A5 (enExample) 2018-08-09
JP6614619B2 JP6614619B2 (ja) 2019-12-04

Family

ID=51752358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511182A Active JP6614619B2 (ja) 2014-08-29 2015-08-28 シグナル伝達系

Country Status (18)

Country Link
US (2) US10654927B2 (enExample)
EP (2) EP3981417A1 (enExample)
JP (1) JP6614619B2 (enExample)
KR (1) KR102222615B1 (enExample)
CN (1) CN106573989B (enExample)
AU (1) AU2015308243B2 (enExample)
BR (1) BR112017003906A2 (enExample)
CA (1) CA2955668A1 (enExample)
CL (1) CL2017000438A1 (enExample)
ES (1) ES2910008T3 (enExample)
GB (1) GB201415347D0 (enExample)
IL (1) IL250101B (enExample)
MX (1) MX376613B (enExample)
NZ (1) NZ728674A (enExample)
RU (1) RU2731638C2 (enExample)
SG (1) SG11201700171VA (enExample)
WO (1) WO2016030691A1 (enExample)
ZA (1) ZA201700466B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
HRP20201906T1 (hr) 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
EP3288570A4 (en) * 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
JP2018515123A (ja) 2015-05-18 2018-06-14 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CA3030003A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
CN110114371A (zh) 2016-11-11 2019-08-09 奥托路斯有限公司 嵌合抗原受体
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
BR112019020001A2 (pt) 2017-03-27 2020-04-28 Nat Univ Singapore linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
CA3062727A1 (en) * 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
CN111164203A (zh) * 2017-08-02 2020-05-15 奥托路斯有限公司 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞
CN107475276A (zh) * 2017-09-05 2017-12-15 深圳大学 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
EP3774866A1 (en) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
AU2019269118B2 (en) 2018-05-15 2025-02-27 Autolus Limited Chimeric antigen receptor
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
AU2019330347B2 (en) 2018-08-29 2025-07-24 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113383018B (zh) * 2018-09-05 2024-09-10 波赛达治疗公司 同种异体细胞组合物和使用方法
SG11202102781UA (en) 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
WO2021009510A1 (en) 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
GB202104030D0 (en) 2021-03-23 2021-05-05 Autolus Ltd Signalling system
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100566A2 (en) * 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
PT3300745T (pt) * 2013-02-15 2019-11-27 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
MY172897A (en) 2013-05-13 2019-12-13 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
PL3071222T3 (pl) * 2013-11-21 2021-04-19 Ucl Business Ltd Komórka
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US9791929B2 (en) * 2014-10-31 2017-10-17 Elwha Llc Tactile control system
IL301458A (en) * 2014-12-24 2023-05-01 Autolus Ltd A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
BR112018013679A2 (pt) * 2016-01-11 2019-01-22 Univ Leland Stanford Junior proteínas quiméricas e métodos de regulação de expressão gênica
GB201602571D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell

Similar Documents

Publication Publication Date Title
JP2017526361A5 (enExample)
RU2017105515A (ru) Сигнальная система
JP6909844B2 (ja) 細胞
JP7068459B2 (ja) Nyeso tcr
Zhao et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
Dargel et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice
Jamieson et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing
Zhang et al. Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
JP2019530431A5 (enExample)
RU2016124278A (ru) Клетка
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
KR20240063204A (ko) Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
IL268620B2 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
JP2016520074A5 (enExample)
WO2017130223A3 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
JP2021503006A5 (enExample)
JP2017513478A5 (enExample)
JP2019506841A5 (enExample)
JP2020512973A5 (enExample)
JP2019513394A5 (enExample)
US20230149460A1 (en) Methods for generating engineered memory-like nk cells and compositions thereof
JP2020501512A5 (enExample)
JP2021505663A5 (enExample)
JP2022541315A (ja) キメラ抗原受容体及びキメラ刺激受容体を発現する細胞並びにその使用